Cyteir Therapeutics, Inc
Cyteir is developing a revolutionary, low side effect approach to the treatment of cancer and other diseases of the immune system.
- Stage Product In Development
- Industry Biotechnology
- Location Bar Harbor, ME, US
- Currency USD
- Founded June 2012
- Employees 3
- Website cyteir.com
Company Summary
Genomic instability is an ‘Achilles heel’ for many cancers and diseases of the immune system – but has not yet been a focus of therapeutic development efforts. Cyteir is a next generation therapeutics enterprise built on a pioneering approach to targeting genomic instability mechanisms with the objective of developing and commercializing new, effective, and low side effect medicines in oncology and immune diseases.
Team
-
Timothy A RombergerCEO and President
Prior to Cyteir Tim was a Managing Director and Marakon, a small boutique advisory firm that assists multinational companies in the areas of strategy, organizational design and business building. Tim joined Marakon in 1993 and has experience working in North America, Europe and Asia. Tim holds a BS in Economics from the Wharton School at the University of Pennsylvania.
-
Kevin MillsChief Science Officer
Kevin Mills is conducts basic and translational studies, as Associate Professor, at the Jackson Laboratory (Bar Harbor). Dr. Mills is Associate Director for Translational Partnerships in the JAX Cancer Center, Joint Faculty at Tufts Medical School, and a member of the UMaine Graduate School. Dr. Mills has published in many high-profile peer reviewed journals. He earned his doctorate in Biology at the Massachusetts Institute of Technology.
-
David ShawSenior Advisor
Advisors
-
Choate-Hall (Bill Asher, Gerald Quirk, Fangli Chen)LawyerUnconfirmedSarah HostetterAccountantUnconfirmed
Previous Investors
-
Jackson LaboratoryUnconfirmedTim Romberger, Co-FounderUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.